Nouscom
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • Presentations
    • Press Releases
    • Scientific publications
    • Events
  • Contact
Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • Presentations
    • Press Releases
    • Scientific publications
    • Events
  • Contact

Archives

Monthly Archive for: "Novembre, 2017"
Home » Archivi per Novembre 2017
 0

Nouscom’s Neoantigen Vaccine Synergizes with NKTR-214 to Cure Established Tumors in Preclinical Model

Basel, Switzerland – 13 November 2017 Nouscom, an oncology company developing next generation cancer vaccines based on its Exovax platform, today announced preclinical data of its neoantigen [...]

READ MORE
0

Nouscom raises €42 million Series B financing led by new investor Abingworth with participation from 5AM Ventures, LSP and Versant Ventures

Basel, Switzerland – 6 November 2017 Nouscom, an oncology company developing neoantigen cancer vaccines based on its Exovax platform, today announced the completion of a €42 million Series B [...]

READ MORE
Contact
  • NOUSCOM
  • info@nouscom.com
  • nouscom.com
Our Privacy

Privacy Policy & Cookie Low

Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

© Copyright 2018 | Made with by
error: Content is protected !!!